MedTrace Logo

RESOLUTE ONYX China RCT Study

NCT03466151 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2026-04-22

No results posted yet for this study

Summary

It is a randomized controlled trial to evaluate the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in comparison with the Medtronic Resolute Integrity™ Zotarolimus-Eluting coronary stent system in the treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) in China.

Conditions

Interventions

DEVICE

Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements

DEVICE

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System

Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements

Sponsors & Collaborators

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • Yongjian Wu, MD · Fuwai Hospital, Chinese Academy of Medical Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2021-02-12
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03466151 on ClinicalTrials.gov